{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:08:39Z","timestamp":1794956919599,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pharmacosmos A\/S"},{"DOI":"10.13039\/501100000291","name":"Kidney Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000291","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Iron deficiency commonly affects patients with chronic kidney disease and has an important burden in disease trajectory and quality of life; nonetheless current guidelines do not advocate treatment of iron-deficiency without anemia in this patient group. Concerns exist regarding the potential effects of intravenous iron on oxidative stress, inflammation, and endothelial function. As part of a multicenter double-blinded randomized controlled clinical trial, we examined the effects of a single dose of intravenous iron vs. placebo on biomarkers of oxidative stress, inflammation and endothelial function in non-anemic iron deficient patients (serum ferritin\u2009&lt;\u2009100\u00a0\u03bcg\/L and\/or transferrin saturation\u2009&lt;\u200920%) with chronic kidney disease (stage 3b-5). Fifty-four individuals were randomized to receive ferric derisomaltose (n\u2009=\u200926) or placebo (n\u2009=\u200928). Ferric derisomaltose was associated with a non-significant decrease in mean F2-isoprostane and no effect on thiobarbituric acid reactive substances when compared to placebo throughout follow up. No effect on inflammatory markers was observed. A modest but statistically significant rise in E-selectin was noted in the intravenous iron group at 1\u00a0month and 3\u00a0month follow-up (p\u2009=\u20090.030 and p\u2009=\u20090.002 respectively). These results suggest ferric derisomaltose administration in non-dialysis dependent chronic kidney disease patients who are iron deficient does not induce prolonged oxidative stress or inflammation. Larger trials are required to quantify the benefit of intravenous iron administration in this patient group.<\/jats:p>","DOI":"10.1038\/s41598-022-10717-8","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T10:03:29Z","timestamp":1651053809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Analysis of oxidative stress, inflammation and endothelial function following intravenous iron in chronic kidney disease in the Iron and Heart Trial"],"prefix":"10.1038","volume":"12","author":[{"given":"Xenophon","family":"Kassianides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Allgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain C.","family":"Macdougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"10717_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/ckj\/sfz091","volume":"13","author":"MMY Wong","year":"2020","unstructured":"Wong, M. M. Y. et al. Anemia and iron deficiency among chronic kidney disease Stages 3\u20135ND patients in the chronic kidney disease outcomes and practice patterns study: Often unmeasured, variably treated. Clin. Kidney J. 13, 613\u2013624 (2020).","journal-title":"Clin. Kidney J."},{"key":"10717_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000496492","volume":"142","author":"A Gafter-Gvili","year":"2019","unstructured":"Gafter-Gvili, A., Schechter, A. & Rozen-Zvi, B. Iron deficiency anemia in chronic kidney disease. Acta Haematol. 142, 44\u201350 (2019).","journal-title":"Acta Haematol."},{"key":"10717_CR3","unstructured":"KIDGO Work Group and Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney International Supplements Vol. 2. http:\/\/kdigo.org\/home\/guidelines\/anemia-in-ckd\/; http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2157171615310777 (2012)."},{"key":"10717_CR4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jacbts.2019.08.009","volume":"5","author":"K Ghafourian","year":"2020","unstructured":"Ghafourian, K., Shapiro, J. S., Goodman, L. & Ardehali, H. Iron and heart failure: Diagnosis, therapies, and future directions. JACC Basic Transl. Sci. 5, 300\u2013313 (2020).","journal-title":"JACC Basic Transl. Sci."},{"key":"10717_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","volume":"380","author":"I Macdougall","year":"2019","unstructured":"Macdougall, I. et al. Intravenous iron in patients undergoing maintenance hemodialysis. N. Engl. J. Med. 380, 447\u2013458 (2019).","journal-title":"N. Engl. J. Med."},{"key":"10717_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa011","author":"S Bhandari","year":"2020","unstructured":"Bhandari, S. et al. Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: The FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol. Dial. Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfaa011 (2020).","journal-title":"Nephrol. Dial. Transplant."},{"key":"10717_CR7","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1681\/ASN.2007101084","volume":"19","author":"KL Kuo","year":"2008","unstructured":"Kuo, K. L., Hung, S. C., Wei, Y. H. & Tarng, D. C. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J. Am. Soc. Nephrol. 19, 1817\u20131826 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"10717_CR8","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1681\/ASN.2013080838","volume":"25","author":"KL Kuo","year":"2014","unstructured":"Kuo, K. L., Hung, S. C., Lee, T. S. & Tarng, D. C. Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. J. Am. Soc. Nephrol. 25, 2596\u20132606 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"10717_CR9","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1097\/01.ASN.0000130149.18412.56","volume":"15","author":"B Scheiber-Mojdehkar","year":"2004","unstructured":"Scheiber-Mojdehkar, B., Lutzky, B., Schaufler, R., Sturm, B. & Goldenberg, H. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: No correlation to peroxide generation. J. Am. Soc. Nephrol. 15, 1648\u20131655 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"10717_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/14740338.2021.1853098","volume":"20","author":"X Kassianides","year":"2021","unstructured":"Kassianides, X., Hazara, A. M. & Bhandari, S. Improving the safety of intravenous iron treatments for patients with chronic kidney disease. Expert Opin. Drug Saf. 20, 23\u201335 (2021).","journal-title":"Expert Opin. Drug Saf."},{"key":"10717_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/ph11030082","volume":"11","author":"S Bhandari","year":"2018","unstructured":"Bhandari, S., Pereira, D. I. A., Chappell, H. F. & Drakesmith, H. Intravenous irons: From basic science to clinical practice. Pharmaceuticals 11, 82 (2018).","journal-title":"Pharmaceuticals"},{"key":"10717_CR12","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ejpb.2011.03.016","volume":"78","author":"MR Jahn","year":"2011","unstructured":"Jahn, M. R. et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer\u00ae), a new intravenous iron preparation and its clinical implications. Eur. J. Pharm. Biopharm. 78, 480\u2013491 (2011).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10717_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10534-011-9409-6","volume":"24","author":"AB Pai","year":"2011","unstructured":"Pai, A. B., Conner, T., McQuade, C. R., Olp, J. & Hicks, P. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. Biometals 24, 603\u2013613 (2011).","journal-title":"Biometals"},{"key":"10717_CR14","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/sj.ki.5002422","volume":"72","author":"R Agarwal","year":"2007","unstructured":"Agarwal, R., Rizkala, A. R., Kaskas, M. O., Minasian, R. & Trout, J. R. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int. 72, 638\u2013642 (2007).","journal-title":"Kidney Int."},{"key":"10717_CR15","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.3324\/haematol.2020.250803","volume":"106","author":"MW Garbowski","year":"2020","unstructured":"Garbowski, M. W. et al. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways. Haematologica 106, 2885\u20132896 (2020).","journal-title":"Haematologica"},{"key":"10717_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/9152732","volume":"2016","author":"N Panth","year":"2016","unstructured":"Panth, N., Paudel, K. R. & Parajuli, K. Reactive oxygen species: A key hallmark of cardiovascular disease. Adv. Med. 2016, 1\u201312 (2016).","journal-title":"Adv. Med."},{"key":"10717_CR17","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.33549\/physiolres.933589","volume":"66","author":"P Kraml","year":"2017","unstructured":"Kraml, P. The role of iron in the pathogenesis of atherosclerosis. Physiol. Res. 66, S55\u2013S67 (2017).","journal-title":"Physiol. Res."},{"key":"10717_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/jcla.20335","volume":"23","author":"JH Yoo","year":"2009","unstructured":"Yoo, J. H. et al. Oxidative status in iron-deficiency anemia. J. Clin. Lab. Anal. 23, 319\u2013323 (2009).","journal-title":"J. Clin. Lab. Anal."},{"key":"10717_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/ph11040103","volume":"11","author":"F Nuhu","year":"2018","unstructured":"Nuhu, F. & Bhandari, S. Oxidative stress and cardiovascular complications in chronic kidney disease, the impact of anaemia. Pharmaceuticals 11, 103 (2018).","journal-title":"Pharmaceuticals"},{"key":"10717_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1159\/000507872","volume":"51","author":"S Bhandari","year":"2020","unstructured":"Bhandari, S., Allgar, V., Lamplugh, A., MacDougall, I. C. & Kalra, P. A. Protocol and Baseline data of a multicentre prospective double-blinded randomized study of intravenous iron on functional status in patients with chronic kidney disease. Am. J. Nephrol. 51, 493\u2013500 (2020).","journal-title":"Am. J. Nephrol."},{"key":"10717_CR21","doi-asserted-by":"crossref","unstructured":"Bhandari, S., Allgar, V., Lamplugh, A., Macdougall, I. & Kalra, P. A. A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status. BMC Nephrol. 22 (2021).","DOI":"10.1186\/s12882-021-02308-y"},{"key":"10717_CR22","doi-asserted-by":"crossref","unstructured":"Kassianides, X., Hazara, A. M., Macdougall, I. C., Kalra, P. A. & Bhandari, S. The impact of intravenous iron on renal injury and function markers in patients with chronic kidney disease and iron deficiency without anemia. Kidney Int. Rep. (2021) (in press).","DOI":"10.1016\/j.ekir.2021.11.002"},{"key":"10717_CR23","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/ckj\/sfaa212","volume":"14","author":"L del Vecchio","year":"2021","unstructured":"del Vecchio, L. et al. Intravenous iron therapy and the cardiovascular system: Risks and benefits. Clin. Kidney J. 14, 1067\u20131076 (2021).","journal-title":"Clin. Kidney J."},{"key":"10717_CR24","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jdiacomp.2015.05.017","volume":"29","author":"H Aljwaid","year":"2015","unstructured":"Aljwaid, H., White, D. L., Collard, K. J., Moody, A. J. & Pinkney, J. H. Non-transferrin-bound iron is associated with biomarkers of oxidative stress, inflammation and endothelial dysfunction in type 2 diabetes. J. Diabetes Complicat. 29, 943\u2013949 (2015).","journal-title":"J. Diabetes Complicat."},{"key":"10717_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050295","volume":"7","author":"KL Kuo","year":"2012","unstructured":"Kuo, K. L. et al. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS\u00a0One 7, e50295 (2012).","journal-title":"PLoS\u00a0One"},{"key":"10717_CR26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jpba.2013.08.005","volume":"86","author":"S F\u00fctterer","year":"2013","unstructured":"F\u00fctterer, S., Andrusenko, I., Kolb, U., Hofmeister, W. & Langguth, P. Structural characterization of iron oxide\/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J. Pharm. Biomed. Anal. 86, 151\u2013160 (2013).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10717_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1080\/08860220802599106","volume":"31","author":"A Ganguli","year":"2009","unstructured":"Ganguli, A. et al. Lipid peroxidation products formation with various intravenous iron preparations in chronic kidney disease. Ren. Fail. 31, 106\u2013110 (2009).","journal-title":"Ren. Fail."},{"key":"10717_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125272","volume":"10","author":"JR Connor","year":"2015","unstructured":"Connor, J. R., Zhang, X., Nixon, A. M., Webb, B. & Perno, J. R. Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations. PLoS\u00a0One 10, e0125272 (2015).","journal-title":"PLoS\u00a0One"},{"key":"10717_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.23876\/j.krcp.20.120","volume":"40","author":"X Kassianides","year":"2021","unstructured":"Kassianides, X., Gordon, A., Sturmey, R. & Bhandari, S. The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: A randomized controlled pilot study. Kidney Res. Clin. Pract. 40, 89\u201398 (2021).","journal-title":"Kidney Res. Clin. Pract."},{"key":"10717_CR30","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.clnu.2016.02.003","volume":"36","author":"T Mero\u00f1o","year":"2017","unstructured":"Mero\u00f1o, T. et al. Oxidative stress, HDL functionality and effects of intravenous iron administration in women with iron deficiency anemia. Clin. Nutr. 36, 552\u2013558 (2017).","journal-title":"Clin. Nutr."},{"key":"10717_CR31","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1093\/ndt\/gfr711","volume":"27","author":"A Martin-Malo","year":"2012","unstructured":"Martin-Malo, A. et al. Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol. Dial. Transplant. 27, 2465\u20132471 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"10717_CR32","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1093\/ndt\/gft524","volume":"29","author":"LH Fell","year":"2014","unstructured":"Fell, L. H. et al. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol. Dial. Transplant. 29, 809\u2013822 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"key":"10717_CR33","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1159\/000107928","volume":"27","author":"P Malindretos","year":"2007","unstructured":"Malindretos, P. et al. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: A comparative study between iron sucrose and iron dextran. Am. J. Nephrol. 27, 572\u2013579 (2007).","journal-title":"Am. J. Nephrol."},{"key":"10717_CR34","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1161\/01.CIR.0000035250.66458.67","volume":"106","author":"T Dr\u00fceke","year":"2002","unstructured":"Dr\u00fceke, T. et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106, 2212\u20132217 (2002).","journal-title":"Circulation"},{"key":"10717_CR35","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.3390\/molecules25122835","volume":"25","author":"I Tvaro\u0161ka","year":"2020","unstructured":"Tvaro\u0161ka, I., Selvaraj, C. & Ko\u010da, J. Selectins\u2014The two Dr. Jekyll and Mr. Hyde faces of adhesion molecules\u2014A review. Molecules 25, 2835 (2020).","journal-title":"Molecules"},{"key":"10717_CR36","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1161\/01.ATV.0000147406.00871.b3","volume":"24","author":"AER Kartikasari","year":"2004","unstructured":"Kartikasari, A. E. R. et al. Intracellular labile iron modulates adhesion of human monocytes to human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 24, 2257\u20132262 (2004).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10717_CR37","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1365-2362.2006.01709.x","volume":"36","author":"AER Kartikasari","year":"2006","unstructured":"Kartikasari, A. E. R. et al. Iron enhances endothelial cell activation in response to Cytomegalovirus or Chlamydia pneumoniae infection. Eur. J. Clin. Investig. 36, 743\u2013752 (2006).","journal-title":"Eur. J. Clin. Investig."},{"key":"10717_CR38","doi-asserted-by":"publisher","first-page":"F579","DOI":"10.1152\/ajprenal.00442.2014","volume":"308","author":"D Taylor","year":"2015","unstructured":"Taylor, D., Bhandari, S. & Seymour, A. M. L. Mitochondrial dysfunction in uremic cardiomyopathy. Am. J. Physiol. Renal Physiol. 308, F579\u2013F587 (2015).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10717_CR39","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/antiox8100498","volume":"8","author":"F Nuhu","year":"2019","unstructured":"Nuhu, F., Seymour, A. M. & Bhandari, S. Impact of intravenous iron on oxidative stress and mitochondrial function in experimental chronic kidney disease. Antioxidants 8, 498 (2019).","journal-title":"Antioxidants"},{"key":"10717_CR40","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jacc.2007.07.029","volume":"50","author":"JE Toblli","year":"2007","unstructured":"Toblli, J. E., Lombra\u00f1a, A., Duarte, P. & di Gennaro, F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J. Am. Coll. Cardiol. 50, 1657\u20131665 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"10717_CR41","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.hlc.2014.12.161","volume":"24","author":"JE Toblli","year":"2015","unstructured":"Toblli, J. E., di Gennaro, F. & Rivas, C. Changes in echocardiographic parameters in iron deficiency patients with heart failure and chronic kidney disease treated with intravenous iron. Heart Lung Circ. 24, 686\u2013695 (2015).","journal-title":"Heart Lung Circ."},{"key":"10717_CR42","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1161\/CIRCULATIONAHA.118.038516","volume":"139","author":"G Charles-Edwards","year":"2019","unstructured":"Charles-Edwards, G. et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency: FERRIC-HF II randomized mechanistic trial. Circulation 139, 2386\u20132398 (2019).","journal-title":"Circulation"},{"key":"10717_CR43","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1186\/s12882-020-02180-2","volume":"21","author":"PA Kalra","year":"2020","unstructured":"Kalra, P. A. et al. NIMO-CKD-UK: A real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease. BMC Nephrol. 21, 539 (2020).","journal-title":"BMC Nephrol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10717-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10717-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10717-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T02:26:15Z","timestamp":1669343175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10717-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10717"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10717-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"12 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"XK and VA have no conflicts of interest. SB, IM and PK have received honorarium for lectures, attended expert opinion committees and received educational funds to attend international Nephrology meetings from Pharmacosmos A\/S and Vifor Pharma.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6853"}}